Wet Age-related Macular Degeneration Clinical Trial
Official title:
Study Comparing Early Extension of Aflibercept and Brolucizumab in Wet AMD (SPARROW)
The currently widely established and preferred protocol for the treatment of wet age-related macular degeneration includes a loading phase of three monthly injections without interim adaptation or treatment according to disease activity, thereafter following a T&E strategy with treatment adaptation in increments of 2-4 weeks according to disease activity. Based on pharmacological considerations regarding the vitreal half-life of the drugs, the aim of this prospective explorative study is to test whether an early extension of treatment intervals without a loading phase is an option without compromising functional outcomes. Based on a superiority of Afl compared to Ran with regard to achieving a dry retina after one year and based on studies, but in the absence of real-life experience with Bro, it seems of interest to test how far Afl and Bro are comparable in terms of their potential to extend the treatment intervals over 12 months, the time to dryness of the retina, and number of injections. Also, it is of high clinical relevance to demonstrate efficacy with longer initial treatment intervals compared to the current possibly over-treating loading-phase with three four-weekly injections.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00138632 -
Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
| Terminated |
NCT04594681 -
A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration
|
Phase 1 | |
| Completed |
NCT03585556 -
AAVCAGsCD59 for the Treatment of Wet AMD
|
Phase 1 | |
| Completed |
NCT03362190 -
ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
|
Phase 2 | |
| Not yet recruiting |
NCT04564937 -
The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04504123 -
MMP-9 Inhibition for Recalcitrant Wet AMD
|
Phase 2 | |
| Terminated |
NCT02005133 -
A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics
|
N/A | |
| Completed |
NCT01016873 -
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
|
Phase 2 | |
| Completed |
NCT03748784 -
ADVM-022 Intravitreal Gene Therapy for Wet AMD
|
Phase 1 | |
| Recruiting |
NCT04468997 -
The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD)
|
Phase 1 | |
| Completed |
NCT04685369 -
Effectiveness of Anti-VEGF Treatments in Wet AMD in Active Smokers
|
||
| Recruiting |
NCT05297292 -
A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD
|
Phase 2/Phase 3 | |
| Completed |
NCT03939767 -
Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease
|
||
| Completed |
NCT03066258 -
Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial
|
Phase 1/Phase 2 | |
| Terminated |
NCT01086761 -
Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration
|
Phase 1 | |
| Recruiting |
NCT05727397 -
Efficacy and Safety of RC28-E Versus Aflibercept
|
Phase 3 | |
| Completed |
NCT04884399 -
Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD
|
Phase 1 | |
| Withdrawn |
NCT01339949 -
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
|
N/A | |
| Terminated |
NCT00139282 -
A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration
|
Phase 3 | |
| Completed |
NCT04964089 -
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
|
Phase 3 |